Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Bluebird Bio (BLUE) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Bluebird Bio (BLUE) lobbying for?
Summary of Lobbying Data:
Lobbying Firms: Bgr Government Affairs, Bluebird Bio, Inc., Llc, The Nickles Group
General Issues: Health Issues, Budget/Appropriations, Medicare/Medicaid, Government Issues
Specific Issues: Build Back Better Act, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, health disparities, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, More Cures Act, FY 2022 Budget Resolution, H.R. 5376, FDA approval of breakthrough therapies, Cures 2.0, value-based payment arrangements, drug pricing issues related to H.R. 3, PDUFA, Matters affecting medical/health issues, CMC reform
Government Agencies: House of Representatives, FDA, HHS, Senate, CMS
One could infer that Bluebird Bio is lobbying on a variety of health-related issues to have a say in regulations and legislation that could impact the approval, pricing, and accessibility of gene therapies. They are likely concerned with maintaining a favorable regulatory environment for their work in gene therapy and may be seeking to influence decisions around FDA approval of breakthrough therapies and CMC reform. Bluebird Bio could also be seeking to influence healthcare policy more broadly, including value-based payment arrangements and issues related to Medicare/Medicaid. Finally, the company may be advocating for policies that would enhance the FDA’s capacity to approve new therapies more quickly and effectively.
